e-learning
resources
London 2016
Wednesday, 07.09.2016
Lung cancer: therapeutic modalities, re-staging, and follow-up
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Risk factors of febrile neutropenia induced by chemotherapy in lung cancer patients
Shinpei Tsuchida (Miyazaki-shi, Japan), Shinpei Tsuchida, Hironobu Tsubouchi, Akiko Kitamura, Nobuhiro Matsumoto, Masamitsu Nakazato
Source:
International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Session:
Lung cancer: therapeutic modalities, re-staging, and follow-up
Session type:
Poster Discussion
Number:
4842
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Shinpei Tsuchida (Miyazaki-shi, Japan), Shinpei Tsuchida, Hironobu Tsubouchi, Akiko Kitamura, Nobuhiro Matsumoto, Masamitsu Nakazato. Risk factors of febrile neutropenia induced by chemotherapy in lung cancer patients. Eur Respir J 2016; 48: Suppl. 60, 4842
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Prognostic factors for stage IV lung adenocarcinoma patients receiving retreatment with EGFR-TKI
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Chemotherapy in elderly patients with non-small-cell lung cancer in Tunisian respiratory department
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Survival in lung cancer: Associated factors in Tunisian patients
Source: International Congress 2015 – Thoracic oncology around the world: rare cases and local features
Year: 2015
Age related influence of COPD on postoperative pulmonary morbidity in lung cancer patients
Source: Annual Congress 2013 –Oncological thoracic surgery
Year: 2013
Efficiency of erythropoiesis-stimulating agents (ESA) in the treatment of chemotherapy-induced anemia in patients with lung cancer (LC)
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Is the lung cancer in elderly similar to lung cancer in younger patients?
Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer
Year: 2014
Comorbitities, responses and survival in pts with NSCLC
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Mortality in asymptomatic vs. symptomatic patients surgically treated for non-small cell lung cancer (NSCLC)
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013
Survival in patients with lung cancer, with and without self reported cardiovascular disease the HUNT study
Source: International Congress 2014 – Lung function, COPD and inflammation
Year: 2014
Influence of anxiety and depression on one-year survival in lung cancer patients
Source: International Congress 2016 – Quality management and quality of life in lung cancer
Year: 2016
Risk factors for prolonged postoperative air leak-a retrospective analysis of 853 partial lung resections for non-small cell lung cancer
Source: Annual Congress 2013 –Oncological thoracic surgery
Year: 2013
Delay in diagnosis and management of lung cancer in developing countries
Source: International Congress 2016 – Quality management and quality of life in lung cancer
Year: 2016
The prognostic significance of thrombocytopenia during chemotherapy in patients with advanced non-small cell lung cancer
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Evaluation of incidental lung cancer in hospitalized patients with non-respiratory disease
Source: International Congress 2016 – The best clinical approach to lung diseases
Year: 2016
Impact of acute admissions and readmissions in patients with lung cancer for patients and the hospital
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
Prognostic factors for survival in lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Approach to hypersensitivity reactions to chemotherapeutics in patients with lung cancer
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Prevalence and risk factors for postoperative pulmonary complications after lung cancer surgery in patients with early stage of COPD
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Weight loss cutoff level as a key variable related to death risk among advanced lung cancer patients
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Physiological predictors of mortality in high-risk patients undergoing surgery for lung cancer
Source: International Congress 2016 – Clinical aspects of lung cancer
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept